NCT06132620

Clinical Efficacy of Qingxin Zishen Decoction in Treating Menopausal Syndrome and Neuroendocrine Mechanism of Regulating KNDy Neurons

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Yun Chen · Academic / Other
• Sex: Female
• Age: 41 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to determine the effects of estrogen (Fenmotong) and Qingxin Zishen Decoction on the levels of kisspeptin, NKB, and dynorphin expressed in human KNDy neurons Between patients with menopausal syndrome. The aims of the study are as follows: * Find a new neuroendocrine mechanism of Qingxin Zishen Decoction in the treatment of menopausal syndrome. * Evaluate the changes of new neuroendocrine indicators in the clinical treatment of menopausal syndrome. * Develop non-hormonal drugs with definite efficacy in the treatment of menopausal syndrome. Participants will randomly divided into the experimental group and the control group, the experimental group will be oral fenmotong, and the control group will be oral Qingxin Zi Kidney Decoction, and the efficacy, sex hormone levels and neuroendocrine index changes of the two groups will be compared.

Conditions

• Menopause

Interventions

Type	Name	Description
DRUG	Femoston	Fenmorphone (this product is a compound preparation, estradiol tablets contain estradiol 2mg; Estradiol dydrogesterone tablets contain estradiol 2 mg and dydrogesterone 10 mg). Usage: 1 time/day: 1 tablet orally every day, every 28 days as a course of treatment.
DRUG	Qingxin Zishen Decoction	Qingxin Zi Kidney Decoction is a traditional Chinese medicine decoction, after regular decoction, 1 dose/day, divided into 2 doses.

Timeline

• Start date: 2017-04-01
• Primary completion: 2018-06-30
• Completion: 2018-06-30
• First posted: 2023-11-15
• Last updated: 2023-11-15

Locations

1 site across 1 country: China